Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6611 USD | -4.59% | -8.54% | -91.36% |
May. 21 | FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD | CI |
May. 08 | Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
End-of-day quotes
Sector Other Biotechnology & Medical Research
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
4.57M | - | - | - | - | - | |
53.67B | - | |||||
38.86B | ||||||
38.76B | ||||||
27.27B | ||||||
25.91B |
- Stock Market
- Equities
- CING Stock
- Charts Cingulate Inc.
- Sector Chart